ChemoCentryx, Inc., (Nasdaq: CCXI) announced the presentation of positive results from its Phase II CLEAR trial with CCX168 in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE